Monoclonal antibodies (mAbs) are essential reagents for deciphering gene
or protein function and have been a fruitful source of therapeutic and
diagnostic agents. However, developing anticarbohydrate antibodies to target
glycans for those purposes has been less successful because the molecular basis
for glycan-mAb interactions is poorly understood relative to protein- or
peptide-binding mAbs. Here, we report our investigation on glycan-mAb
interactions by using the unique architectural scaffold of 2G12, an antibody
that targets oligomannoses on the HIV-1 glycoprotein gp120, as the template for
engineering highly specifc mAbs to target glycans. We first analyzed 24
different X-ray structures of antiglycan mAbs from the Protein Data Bank to
determine side chain amino acid distributions in of glycan-mAb interactions. We
identified Tyr, Arg, Asn, Ser, Asp, and His as the six most prevalent residues
in the glycan-mAb contacts. We then utilized this information to construct two
phage display libraries in which positions on the heavy chain variable domains
of 2G12 were allowed to vary in restricted manner among Tyr, Asp, Ser, His, Asn,
Thr, Ala and Pro to interrogate the minimal physicochemical requirements for
oligomannose recognition. We characterized 39 variants from Lib1 and 14 variants
from Lib2 following selection against gp120, the results showed that there is a
high degree of malleability within the 2G12 for glycan recognitions. We further
characterized five unique phage clones from both libraries that exhibited a
gp120-specific binding profile. Expression of two of these variants as soluble
mAbs indicated that, while specificity of gp120-binding was retained, the
affinity of these mutants was significantly reduced relative to WT 2G12.
Nonetheiess, the results indicate these is some malleability in the identity of
contact residues and provide a novel insight into the nature of glycan-antibody
interactions and how they may differ from protein-protein binding
interactions.